Imatinib (QTI571) in Pulmonary Arterial Hypertension

Completed · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Arterial Hypertension

In brief

A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).

Key facts

Study ID
NCT00902174
Run by
Novartis Pharmaceuticals
People needed
202
Starts
2009-09-01
Expected to finish
2011-05-01
Last updated by the study team
2016-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.